BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tremfya (guselkumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tremfya (guselkumab)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06651489-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremfya (guselkumab): Phase 2 readout est. (NCT06651489)
DESCRIPTION:Tremfya (guselkumab)\, phase 2.\nStudy: Efficacy of Guselkumab 
 in Treating Hailey Hailey Disease\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06651489
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05004727-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT05004727)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Psoriasis.\nStudy: Multi-Cente
 r PAMPA Study\nEstimated primary completion: 31 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05004727
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tremfya (guselkumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Tremfya (guselkumab)\, phase 2/3.\nStudy: Using a Contact Derma
 titis Model With Biologic Medications to Study Skin Inflammation\nEstimate
 d primary completion: 1 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260163-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06260163)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Study of Guselkumab in Pediatric Participants With Moderately to Severely 
 Active Ulcerative Colitis\nEstimated primary completion: 10 February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06260163
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347095-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05347095)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Participants With Fistulizing\, Perianal Crohn's Disea
 se\nEstimated primary completion: 25 March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05347095
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929210-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT04929210)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Psoriatic Arthritis.\nStudy: A
  Study of Guselkumab Administered Subcutaneously in Bio-naive Participants
  With Active Psoriatic Arthritis Axial Disease\nEstimated primary completi
 on: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gus
 elkumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04929210
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141004-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270605
DTEND;VALUE=DATE:20270606
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT07141004)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Psoriatic Arthritis.\nStudy: A
  Study of Guselkumab Administered Subcutaneously in Treatment of Indian Pa
 rticipants With Psoriatic Arthritis (PsA)\nEstimated primary completion: 5
  June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/guselkuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 141004
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408935-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06408935)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: Trans
 mural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Diseas
 e Patients\nEstimated primary completion: 8 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06408935
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532486-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Tremfya (guselkumab): Phase na readout est. (NCT07532486)
DESCRIPTION:Tremfya (guselkumab)\, phase na\, Psoriasis.\nStudy: A Study to
  Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and E
 xtended-interval Versus Standard-dose in Chinese Participants of Moderate-
 to-severe Plaque Psoriasis\nEstimated primary completion: 10 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07532486
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563323-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270813
DTEND;VALUE=DATE:20270814
SUMMARY:Tremfya (guselkumab): Phase 2 readout est. (NCT06563323)
DESCRIPTION:Tremfya (guselkumab)\, phase 2.\nStudy: Guselkumab in the Treat
 ment of Adults With Pyoderma Gangrenosum (PG)\nEstimated primary completio
 n: 13 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gu
 selkumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06563323
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654751-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT07654751)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Ulcerative Colitis.\nStudy: A 
 Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk
  of Lactating Women Who Are Receiving TREMFYA Therapeutically\nEstimated p
 rimary completion: 31 August 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/guselkumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07654751
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06586281-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tremfya (guselkumab): Phase na readout est. (NCT06586281)
DESCRIPTION:Tremfya (guselkumab)\, phase na\, Psoriatic Arthritis.\nStudy: 
 Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severi
 ty With Guselkumab Therapy\nEstimated primary completion: 1 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06586281
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07310095-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT07310095)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Crohn's Disease.\nStudy: A Stu
 dy to Evaluate the Efficacy of Guselkumab in Chinese Participants With Cro
 hn's Disease (CD)\nEstimated primary completion: 15 September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07310095
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923073-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271027
DTEND;VALUE=DATE:20271028
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT05923073)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab in Pediatric Participants With Moderately to Severely Act
 ive Crohn's Disease\nEstimated primary completion: 27 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05923073
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tremfya (guselkumab): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Tremfya (guselkumab)\, phase 2.\nStudy: Immunosuppressant Manag
 ement in Rheumatology Patients Undergoing Elective Total Shoulder Arthropl
 asty\nEstimated primary completion: January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06398106-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT06398106)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Psoriasis.\nStudy: Proactive T
 DM Versus Standard Use of Biologics in Psoriasis\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 uselkumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06398106
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06916390-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT06916390)
DESCRIPTION:Tremfya (guselkumab)\, phase 4.\nStudy: GUselkumAb inteRvention
  and DIet evaluAtioN for Pouchitis\nEstimated primary completion: 30 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06916390
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05858632-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT05858632)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Psoriasis.\nStudy: Immune Spat
 ial Features of Guselkumab Cutaneous Response\nEstimated primary completio
 n: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/guse
 lkumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05858632
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499232-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT07499232)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Crohn's Disease.\nStudy: A Stu
 dy of Guselkumab Versus Risankizumab in Participants With Moderately to Se
 verely Active Crohn's Disease\nEstimated primary completion: 15 November 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/guselkumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07499232
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616687-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT07616687)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Crohn's Disease.\nStudy: Optim
 al Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Ope
 n Label Interventional\, Multicenter Study\nEstimated primary completion: 
 15 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/guselk
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07616687
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Tremfya (guselkumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Tremfya (guselkumab)\, phase 4\, Psoriasis.\nStudy: Utilization
  of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary c
 ompletion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/guselkumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07352566
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06663332-5@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20311212
DTEND;VALUE=DATE:20311213
SUMMARY:Tremfya (guselkumab): Phase 3 readout est. (NCT06663332)
DESCRIPTION:Tremfya (guselkumab)\, phase 3\, Ulcerative Colitis.\nStudy: A 
 Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants\nE
 stimated primary completion: 12 December 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/guselkumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06663332
URL:https://assetmemo.bio/drug/guselkumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
